To evaluate the efficacy safety and tolerability of 6-week extended interval dosing of Natalizumab (BG00002) switching from treatment with 4-Week Natalizumab standard interval dosing (SID) in relation to continued SID treatment

Brief description of study

The main purpose of this study is to evaluate the efficacy, safety, and tolerability of 6-week extended interval dosing of Natalizumab (BG00002) switching from treatment with 4-Week Natalizumab standard interval dosing (SID) in relation to continued standard interval dosing (SID) treatment.


Clinical Study Identifier: s18-01090
ClinicalTrials.gov Identifier: NCT03689972


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.